Sean Buckley and co-authors from Roche, Takeda, and BioPhorum author CGT [cell & gene therapy] Actors and Process Maps which highlight six common types of CGT showing how the pattern of actors and process blocks varies by therapy type.
The BioPhorum Operations Group (BPOG) established a digital plant maturity model (DPMM) for biopharmaceutical manufacturing to define stages of factory evolution “from simple paper-based plants through to the fully automated and integrated ‘adaptive plant’ of the future.” The model gives organizations a common tool for industry comparison and measurement of progress. It also provides a platform to facilitate collaboration within the life sciences industry and its technology providers.
Traditional manufacturing practices have served the biopharmaceutical industry well for years, but times are changing and a need for speed to market in life sciences while reducing manufacturing costs is putting a focus on enabling real-time release (RTR)....
The BioPhorum CGT Personas and User Stories toolkit details the needs of all the key players involved in end-to-end cell and gene therapy (CGT) processes. It can be used by anyone who wishes to better understand how IT systems can support the manufacture and delivery of CGTs.
One of the key stages delaying and increasing costs in life sciences projects is equipment validation. In fact, it is one of the elements of project completion that project teams are most eager to compress because the value of every incremental improvement is so...
For biotech industries, Emerson offers fundamental automation solutions with quicker uptimes and more consistent batch quality.
In BioPhorum’s MES of the Future Manifesto, Sean and Kate Porter collaborated with other biomanufacturing leaders on requirements for future Manufacturing Execution Systems.
In a Process Instrumentation article, How to ensure reliable pressure transmitter measurement in pharmaceutical applications, Emerson’s Brandon Haschke shares how “Advanced hygienic pressure transmitters can reduce downtime and operating costs thanks to long-term stability that requires fewer calibrations.”
Emerson’s Christian Berg presented Are We There Yet? Tackling Manufacturing Challenges with the Digital Plant at the Pharma Manufacturing World Summit in Boston.
The rapid development of the COVID-19 vaccine has created a dramatic shift in the way the public and life sciences organizations view the manufacturing of pharmaceuticals. In a recent Q&A with Pharma Manufacturing, Nathan Pettus, president of Emerson’s process...
It isn’t news that the global pandemic upended the way we operate our plants. When social distancing trapped our most valuable personnel outside the facilities we rely on, it suddenly meant finding new ways to get critical work done. But the reality is, those changes...
We have witnessed an incredible change the last few years in how life sciences manufacturers deliver treatments. Today’s focus is on fast results, and that means products patients rely on cannot sit on shelves for weeks or months waiting on quality validation. In a...
We invite you to follow us on Facebook, LinkedIn, Twitter and YouTube to keep up to date on all the latest news, events and innovations to help you take on and solve your toughest challenges.
Please do, Just link back to the post and send us a quick note so we can share your work. Thanks!
Our Global Community
The opinions expressed here are the personal opinions of the authors. Content published here is not read or approved by Emerson before it is posted and does not necessarily represent the views and opinions of Emerson.